Navigation Links
Orexigen® Therapeutics Provides a Regulatory Update on Contrave® NDA
Date:6/3/2011

SAN DIEGO, June 3, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced today that it recently met with the Food and Drug Administration (FDA) regarding the New Drug Application for Contrave® (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss.  Orexigen sought the meeting to gain clarity on the approval deficiency stated in the Complete Response letter the Company received on January 31, 2011.  The Complete Response letter requested that the Company conduct a randomized, double-blind, placebo-controlled trial of sufficient size and duration to demonstrate that the risk of major adverse cardiovascular events in overweight and obese subjects treated with Contrave does not adversely affect the drug's benefit-risk profile.  

Orexigen submitted a specific proposal to address the theoretical cardiovascular risk cited in the approval deficiency and also explored approval for a narrowed indication in patients with lower cardiovascular risk until data from the proposed outcomes trial could be reviewed for label expansion.  The Division of Metabolic and Endocrinologic Products (DMEP) advised Orexigen that the proposed cardiovascular outcomes trial would not adequately address the approval deficiency and instead, requested a pre-approval cardiovascular outcomes trial that Orexigen believes is unprecedented and would generate significantly more information than is necessary or feasible.  Additionally, DMEP stated that it would not consider approving Contrave for a narrowed population without first reviewing data from a cardiovascular outcomes trial.  Finally, DMEP said that it intends to hold a general advisory committee early next year to discuss cardiovascular assessment for obesity therapeutics, and that any agreement reached on the desi
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
7. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
11. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Hearing health affects a ... younger, and remain socially and professionally engaged, he should address ... overriding message that the Better Hearing Institute (BHI) ... National Men,s Health Week , which leads up to ... runs from June 10 through June 16. ...
(Date:5/23/2013)... , May 23, 2013  A recently published ... Houston, Texas , demonstrates that 3D ... increasing cancer detection. The study, "Implementation ... Observational Study," was led by Stephen L. ... issue of the American Journal of Roentgenology ...
(Date:5/23/2013)... May 23, 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, ... companies, based on intellectual property developed and owned ... ,s foremost medical research center, today announced that ... significant funding from the Israeli Ministry of Industry ... to support product development and advance clinical trials. ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... , CAMBRIDGE, Mass., Nov. 19 Ligon Discovery, ... find drugs against high-value targets, today announced that it ... Ventures. The company will use the capital to complete ... high-value disease protein targets. With this investment, incTANK Ventures ...
... , Part of ... Md., Nov. 19 The U.S. Food and Drug ... the International Internet Week of Action (IIWA), intended to ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , During the effort, the FDA,s Office ...
Cached Medicine Technology:Cambridge-based Ligon Discovery Raises $1M in Seed Funding 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 3UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2
(Date:5/23/2013)... Utah (PRWEB) May 23, 2013 Today, ... employer mandate . Zane Benefits, which provides comprehensive ... is the leader in defined contribution plans ... care reform, a common question from employees is “does ... Zane Benefits’ website, not necessarily. The health care reform ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Onlinefitnessreview.com recently ... Blast Diet to determine what makes this diet work ... published review highlights three main components of the program: ... a positive mindset and the personal motivation that is ... every 7 days to keep the metabolism rate in ...
(Date:5/23/2013)... City, UT (PRWEB) May 23, 2013 ... , a comprehensive radiology learning environment for all ... prebuilt lessons and assessments, transforms the learning experience ... radiology curriculum. , “Until RADPrimer 3.0, ... second to none,” comments Dr. B.J. Manaster, Professor ...
(Date:5/23/2013)... modified version of the polio virus might one ... Scientists at Duke Cancer Institute said the ... engineered form of the virus that is harmless ... therapy shows promise in the treatment of glioblastoma, ... said. "These early results are intriguing," principal ...
(Date:5/23/2013)... Plano, TX (PRWEB) May 23, 2013 ... the Marketplace , Chaplains have been a part of ... this Memorial Day, like those preceding it, these men ... service to the United States of America. As ... trend of their migration to the workplace chaplaincy world. ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on the Employer Mandate 2Health News:Zane Benefits Publishes New Information on the Employer Mandate 3Health News:Onlinefitnessreview.com Publishes 7 Day Belly Blast Diet Review 2Health News:RADPrimer 3.0 Introduces Comprehensive Radiology Training Curriculum 2Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 3
... technology called the Cone beam computerized tomography (CBCT) is ... complicated oral problems.// ,J. Martin Palomo and ... Case Western Reserve University School of Dental Medicine and ... dental health and biological sciences at the University of ...
... two protein complexes which is found to protect cell ... number of chromosomes leading to cell instability which leads ... research team from Mayo Clinic have found that the ... which maintains the euploidy state in the cell and ...
... Ontario’s hospitals are getting longer, according to Government data which ... the Conservative health critic.// The waiting time rose from 34 ... cancer surgery, while it rose from 139 days to 142 ... days for cardiac surgeries, while in the case of angioplasty, ...
... reported to have been cracked by the researchers from ... treatment of the ailment which causes severe diarrhea,// abdominal ... Dasval. The strain has caused infections to breakout in ... now commence for the other antibiotic resistance genes and ...
... Research Institute (SERI) found that increasing the contrast of ... to the visually impaired. // ,The U.S. study ... to help millions suffering eye diseases. People who may ... macular degeneration, diabetic retinopathy and other causes of low ...
... president of Sandia National Laboratories, Gerry Yonas was the first to ... ,This led to the development of the BiNational Sustainability Laboratory (BNSL), ... Teresa. This will mainly augment the border security force and ... Mexico. ,The monetary inputs for the lab ...
Cached Medicine News:Health News:New Computerized Imaging Systems Help In Better Dental Treatment Planning 2Health News:Visually impaired prefer specially enhanced TV 2Health News:Visually impaired prefer specially enhanced TV 3
... for the quantitative determination of ... kinetic, lag phase of less ... linear phase of at least ... Linearity: 100 mg/dL (35.6 mmol/L ...
For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
... the first microplate spectrophotometer designed specifically to ... per week. With rugged hardware, proven optical ... the barrier of traditional spectrophotometry to obtain ... can easily read up to eight, 1 ...
The PerkinElmer LS 45 Luminescence spectrometer offers versatility, reliability and ease-of-use for routine analyses in an affordable package....
Medicine Products: